NASDAQ:CLSD - Clearside Biomedical Stock Price, Price Target & More

$11.42 -0.12 (-1.04 %)
(As of 04/19/2018 07:30 AM ET)
Previous Close$11.54
Today's Range$11.14 - $12.19
52-Week Range$5.30 - $15.06
Volume599,100 shs
Average Volume819,120 shs
Market Capitalization$368.28 million
P/E Ratio-4.90
Dividend YieldN/A
Beta-7.02

About Clearside Biomedical (NASDAQ:CLSD)

Clearside Biomedical logoClearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631

Debt

Debt-to-Equity Ratio0.22%
Current Ratio2.90%
Quick Ratio2.90%

Price-To-Earnings

Trailing P/E Ratio-4.90
Forward P/E Ratio-5.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$340,000.00
Price / Sales1,071.80
Cash FlowN/A
Price / CashN/A
Book Value$0.84 per share
Price / Book13.60

Profitability

EPS (Most Recent Fiscal Year)($2.33)
Net Income$-58,970,000.00
Net Margins-17,094.20%
Return on Equity-131.22%
Return on Assets-96.00%

Miscellaneous

Employees34
Outstanding Shares31,910,000

How to Become a New Pot Stock Millionaire

Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical (NASDAQ:CLSD) released its earnings results on Wednesday, March, 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.05. The firm earned $0.06 million during the quarter, compared to the consensus estimate of $0.10 million. Clearside Biomedical had a negative net margin of 17,094.20% and a negative return on equity of 131.22%. View Clearside Biomedical's Earnings History.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Clearside Biomedical.

What price target have analysts set for CLSD?

5 equities research analysts have issued 12 month price targets for Clearside Biomedical's shares. Their predictions range from $15.00 to $29.00. On average, they anticipate Clearside Biomedical's share price to reach $21.80 in the next year. View Analyst Ratings for Clearside Biomedical.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,507,557 shares, an increase of 56.1% from the February 28th total of 965,841 shares. Based on an average trading volume of 3,756,703 shares, the short-interest ratio is currently 0.4 days. Currently, 8.3% of the shares of the stock are sold short.

Who are some of Clearside Biomedical's key competitors?

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the folowing people:
  • Christy L. Shaffer Ph.D., Chairman of the Board (Age 59)
  • Daniel H. White, President, Chief Executive Officer, Director (Age 50)
  • Charles A. Deignan, Chief Financial Officer (Age 52)
  • Glenn Noronha Ph.D., Chief Scientific Officer (Age 52)
  • Rafael V. Andino, Vice President - Engineering & Manufacturing
  • George Lasezkay J.D., Director (Age 65)
  • Gerald D. Cagle Ph.D., Independent Director (Age 72)
  • Richard J. Croarkin, Independent Director (Age 62)
  • William D. Humphries, Independent Director (Age 50)
  • Clay B. Thorp, Independent Director (Age 48)

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Has Clearside Biomedical been receiving favorable news coverage?

News headlines about CLSD stock have been trending very positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Clearside Biomedical earned a media sentiment score of 0.53 on Accern's scale. They also gave media stories about the company an impact score of 45.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $11.42.

How big of a company is Clearside Biomedical?

Clearside Biomedical has a market capitalization of $368.28 million and generates $340,000.00 in revenue each year. The company earns $-58,970,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Clearside Biomedical employs 34 workers across the globe.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]


MarketBeat Community Rating for Clearside Biomedical (CLSD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  281
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Clearside Biomedical (NASDAQ:CLSD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Clearside Biomedical in the last 12 months. Their average twelve-month price target is $21.80, suggesting that the stock has a possible upside of 90.89%. The high price target for CLSD is $29.00 and the low price target for CLSD is $15.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.80$21.80$20.00$20.50
Price Target Upside: 90.89% upside82.43% upside166.31% upside156.25% upside

Clearside Biomedical (NASDAQ:CLSD) Consensus Price Target History

Price Target History for Clearside Biomedical (NASDAQ:CLSD)

Clearside Biomedical (NASDAQ:CLSD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2018WedbushReiterated RatingOutperform$29.00LowView Rating Details
3/6/2018Needham & Company LLCBoost Price TargetBuy -> Buy$18.00 -> $22.00HighView Rating Details
3/6/2018JPMorgan ChaseReiterated RatingOverweight -> Overweight$15.00 -> $18.00HighView Rating Details
3/5/2018JMP SecuritiesReiterated RatingOutperform$25.00HighView Rating Details
10/25/2017CowenReiterated RatingBuyN/AView Rating Details
10/24/2016Stifel NicolausBoost Price TargetBuy$13.00 -> $23.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Clearside Biomedical (NASDAQ:CLSD) Earnings History and Estimates Chart

Earnings by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Clearside Biomedical (NASDAQ:CLSD) Earnings Estimates

2018 EPS Consensus Estimate: ($2.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.50)($0.50)($0.50)
Q2 20181($0.50)($0.50)($0.50)
Q3 20181($0.51)($0.51)($0.51)
Q4 20181($0.59)($0.59)($0.59)

Clearside Biomedical (NASDAQ CLSD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.64)N/AView Earnings Details
3/14/2018Q4 2017($0.70)($0.65)$0.10 million$0.06 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.55)($0.72)$0.01 million$0.16 millionViewN/AView Earnings Details
8/9/20176/30/2017($0.41)($0.54)$0.13 millionViewListenView Earnings Details
5/10/20173/31/2017($0.44)($0.41)$0.01 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.33)($0.45)$0.01 million$0.01 millionViewN/AView Earnings Details
11/9/20169/30/2016($0.45)($0.28)$0.01 million$0.01 millionViewListenView Earnings Details
8/11/2016Q2($0.32)($0.62)$0.01 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Clearside Biomedical (NASDAQ:CLSD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Clearside Biomedical (NASDAQ CLSD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 20.90%
Institutional Ownership Percentage: 38.63%
Insider Trading History for Clearside Biomedical (NASDAQ:CLSD)
Institutional Ownership by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Clearside Biomedical (NASDAQ CLSD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/23/2018Charles A DeignanCFOBuy500$11.79$5,895.0066,356View SEC Filing  
3/22/2018Gerald D CagleDirectorBuy7,500$11.89$89,175.0023,441View SEC Filing  
12/7/2017Clay ThorpDirectorSell5,000$6.13$30,650.00View SEC Filing  
12/5/2017Clay ThorpDirectorSell15,000$6.37$95,550.00View SEC Filing  
11/16/2017Clay ThorpDirectorSell35,000$7.00$245,000.00View SEC Filing  
11/14/2017Clay ThorpDirectorSell15,000$7.02$105,300.00View SEC Filing  
10/19/2017Daniel H WhiteInsiderSell8,000$7.82$62,560.00477,935View SEC Filing  
10/5/2017Clay ThorpDirectorSell35,000$8.57$299,950.00View SEC Filing  
9/15/2017Clay ThorpDirectorSell24,500$7.52$184,240.00View SEC Filing  
9/14/2017Clay ThorpDirectorSell6,000$7.52$45,120.00View SEC Filing  
9/13/2017Clay ThorpDirectorSell8,500$7.49$63,665.00View SEC Filing  
9/8/2017Daniel H WhiteInsiderSell16,000$7.57$121,120.00486,935View SEC Filing  
8/15/2017Christy L ShafferDirectorBuy1,100$7.00$7,700.004,400View SEC Filing  
8/14/2017Charles A DeignanCFOBuy1,000$7.07$7,070.0065,309View SEC Filing  
8/11/2017Gerald D CagleDirectorBuy5,000$7.08$35,400.0015,941View SEC Filing  
8/9/2017Clay ThorpDirectorSell24,500$7.57$185,465.00View SEC Filing  
8/8/2017Clay ThorpDirectorSell5,000$7.98$39,900.00View SEC Filing  
8/7/2017Clay ThorpDirectorSell4,500$8.02$36,090.00View SEC Filing  
7/20/2017Daniel H WhiteInsiderSell8,000$9.75$78,000.00499,967View SEC Filing  
7/19/2017Daniel H WhiteCEOSell3,600$9.79$35,244.00499,967View SEC Filing  
6/14/2017Daniel H WhiteInsiderSell8,000$7.89$63,120.00504,067View SEC Filing  
6/13/2017Daniel H WhiteCEOSell3,600$7.78$28,008.00504,067View SEC Filing  
5/22/2017Christy L ShafferDirectorBuy1,100$8.00$8,800.003,300View SEC Filing  
5/19/2017Clay ThorpDirectorSell24,000$8.36$200,640.00View SEC Filing  
5/18/2017Daniel H WhiteInsiderSell8,000$8.41$67,280.00511,267View SEC Filing  
5/17/2017Clay ThorpDirectorSell44,485$8.63$383,905.55View SEC Filing  
5/16/2017Clay ThorpDirectorSell9,544$8.61$82,173.84View SEC Filing  
5/15/2017Clay ThorpDirectorSell15,941$8.94$142,512.54View SEC Filing  
4/19/2017Clay ThorpDirectorSell68,485$7.46$510,898.10View SEC Filing  
4/18/2017Clay ThorpDirectorSell44,455$7.48$332,523.40View SEC Filing  
4/17/2017Clay ThorpDirectorSell22,000$7.43$163,460.00View SEC Filing  
4/4/2017Daniel H WhiteInsiderSell8,000$7.55$60,400.00527,217View SEC Filing  
4/3/2017Daniel H WhiteCEOSell3,600$7.56$27,216.00527,217View SEC Filing  
3/20/2017Christy L ShafferDirectorBuy2,200$6.90$15,180.002,200View SEC Filing  
3/16/2017Clay ThorpDirectorSell68,485$6.56$449,261.60View SEC Filing  
2/22/2017Clay ThorpDirectorSell27,000$7.55$203,850.00View SEC Filing  
2/17/2017Clay ThorpDirectorSell41,485$7.60$315,286.00View SEC Filing  
1/20/2017Clay ThorpDirectorSell68,485$8.53$584,177.05View SEC Filing  
1/19/2017Venture Advisors Iii HatterasInsiderSell25,301$8.63$218,347.63View SEC Filing  
6/7/2016Clay ThorpDirectorSell138$7.00$966.00View SEC Filing  
6/7/2016Venture Advisors Iv S HatterasMajor ShareholderBuy414,286$7.00$2,900,002.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Clearside Biomedical (NASDAQ CLSD) News Headlines

Source:
DateHeadline
Why Clearside Biomedical, Inc. Stock Gained 66.1% MarchWhy Clearside Biomedical, Inc. Stock Gained 66.1% March
finance.yahoo.com - April 13 at 9:31 AM
Clearside Biomedical (CLSD) Cut to "Sell" at ValuEngineClearside Biomedical (CLSD) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM
Clearside Biomedical Inc (CLSD) Receives Consensus Recommendation of "Hold" from AnalystsClearside Biomedical Inc (CLSD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 11 at 3:17 AM
Clearside Biomedicals (CLSD) "Buy" Rating Reiterated at CowenClearside Biomedical's (CLSD) "Buy" Rating Reiterated at Cowen
www.americanbankingnews.com - April 4 at 9:04 PM
Clearside Biomedical Inc (CLSD) Sees Large Increase in Short InterestClearside Biomedical Inc (CLSD) Sees Large Increase in Short Interest
www.americanbankingnews.com - March 30 at 3:38 AM
Clearside Biomedical (CLSD) Lowered to "Strong Sell" at ValuEngineClearside Biomedical (CLSD) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 4:21 PM
Clearside Biomedical Inc (CLSD) Director Purchases $89,175.00 in StockClearside Biomedical Inc (CLSD) Director Purchases $89,175.00 in Stock
www.americanbankingnews.com - March 23 at 10:34 AM
Brokers Issue Forecasts for Clearside Biomedical Incs Q1 2018 Earnings (CLSD)Brokers Issue Forecasts for Clearside Biomedical Inc's Q1 2018 Earnings (CLSD)
www.americanbankingnews.com - March 22 at 9:06 AM
Clearside Biomedical to Present at the 17th Annual Needham Healthcare ConferenceClearside Biomedical to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 9:47 AM
Clearside Biomedical (CLSD) Rating Reiterated by WedbushClearside Biomedical (CLSD) Rating Reiterated by Wedbush
www.americanbankingnews.com - March 20 at 10:42 AM
Clearside Biomedical Inc (CLSD) Receives Consensus Recommendation of "Hold" from BrokeragesClearside Biomedical Inc (CLSD) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 17 at 3:28 AM
3 Hot Junior Biotech Plays3 Hot Junior Biotech Plays
finance.yahoo.com - March 16 at 4:51 PM
Upcoming Conversation With An Expert: Digging Into The Results From Clearsides P3 PEACHTREE Trial - Seeking AlphaUpcoming Conversation With An Expert: Digging Into The Results From Clearside's P3 PEACHTREE Trial - Seeking Alpha
seekingalpha.com - March 16 at 10:04 AM
Form 8-K Clearside Biomedical, For: Mar 14 - StreetInsider.comForm 8-K Clearside Biomedical, For: Mar 14 - StreetInsider.com
www.streetinsider.com - March 16 at 10:04 AM
Clearside Biomedical (CLSD) Posts Quarterly  Earnings Results, Beats Expectations By $0.05 EPSClearside Biomedical (CLSD) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - March 15 at 7:56 AM
Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate UpdateClearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 12:18 PM
With A -144.16% Earnings Drop, Did Clearside BioMedical Inc (NASDAQ:CLSD) Really Underperform?With A -144.16% Earnings Drop, Did Clearside BioMedical Inc (NASDAQ:CLSD) Really Underperform?
finance.yahoo.com - March 14 at 12:18 PM
Clearside Biomedical (CLSD) Upgraded by BidaskClub to "Hold"Clearside Biomedical (CLSD) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - March 10 at 6:34 PM
Clearside Biomedical (CLSD) Prices 6.54M Shares at $13 - StreetInsider.comClearside Biomedical (CLSD) Prices 6.54M Shares at $13 - StreetInsider.com
www.streetinsider.com - March 9 at 4:54 PM
Clearside Biomedical to Present at the Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)Clearside Biomedical to Present at the Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 9 at 4:54 PM
Clearside Biomedical to Report Fourth Quarter and Full Year 2017 Financial Results on March 14, 2018 – Conference Call to FollowClearside Biomedical to Report Fourth Quarter and Full Year 2017 Financial Results on March 14, 2018 – Conference Call to Follow
finance.yahoo.com - March 8 at 4:46 PM
Clearside Biomedical Target of Unusually Large Options Trading (CLSD)Clearside Biomedical Target of Unusually Large Options Trading (CLSD)
www.americanbankingnews.com - March 8 at 8:05 AM
Why Clearside Biomedical Is Up for a Third Straight DayWhy Clearside Biomedical Is Up for a Third Straight Day
finance.yahoo.com - March 7 at 4:42 PM
Traders Purchase High Volume of Clearside Biomedical Call Options (CLSD)Traders Purchase High Volume of Clearside Biomedical Call Options (CLSD)
www.americanbankingnews.com - March 7 at 7:26 AM
Clearside Announces Proposed Public Offering of Common StockClearside Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 6 at 4:38 PM
Why Clearside Biomedical Jumped Higher TodayWhy Clearside Biomedical Jumped Higher Today
finance.yahoo.com - March 6 at 4:38 PM
Clearside Biomedical (CLSD) PT Raised to $18.00Clearside Biomedical (CLSD) PT Raised to $18.00
www.americanbankingnews.com - March 6 at 3:28 PM
Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein OcclusionClearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion
finance.yahoo.com - March 6 at 9:34 AM
Today’s Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and Clearside BioMedicalToday’s Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and Clearside BioMedical
finance.yahoo.com - March 6 at 9:34 AM
Needham & Company LLC Increases Clearside Biomedical (CLSD) Price Target to $22.00Needham & Company LLC Increases Clearside Biomedical (CLSD) Price Target to $22.00
www.americanbankingnews.com - March 6 at 8:42 AM
Why Clearside BioMedical Is Monday’s Biggest WinnerWhy Clearside BioMedical Is Monday’s Biggest Winner
www.msn.com - March 5 at 4:49 PM
Clearside Biomedical (CLSD) Reports Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TAClearside Biomedical (CLSD) Reports Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA
www.streetinsider.com - March 5 at 4:49 PM
Here’s What’s Moving Clearside Biomedical, Inc. (NASDAQ:CLSD) Right NowHere’s What’s Moving Clearside Biomedical, Inc. (NASDAQ:CLSD) Right Now
finance.yahoo.com - March 5 at 4:49 PM
Clearside Biomedicals (CLSD) "Outperform" Rating Reiterated at JMP SecuritiesClearside Biomedical's (CLSD) "Outperform" Rating Reiterated at JMP Securities
www.americanbankingnews.com - March 5 at 1:36 PM
Clearside Biomedical shares surge 53% premarket on news of positive trial of eye disease treatmentClearside Biomedical shares surge 53% premarket on news of positive trial of eye disease treatment
finance.yahoo.com - March 5 at 10:22 AM
Here’s Why Clearside Biomedical Inc (CLSD) Rockets in Pre-Market TradingHere’s Why Clearside Biomedical Inc (CLSD) Rockets in Pre-Market Trading
finance.yahoo.com - March 5 at 10:22 AM
Clearside Biomedical (CLSD) Set to Announce Earnings on MondayClearside Biomedical (CLSD) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM
Clearside Biomedical Schedules Conference Call to Review Topline Results from Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious UveitisClearside Biomedical Schedules Conference Call to Review Topline Results from Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis
finance.yahoo.com - March 2 at 4:42 PM
Clearside Biomedical Announces Organizational Changes Designed to Support Transition to a Commercial-Stage CompanyClearside Biomedical Announces Organizational Changes Designed to Support Transition to a Commercial-Stage Company
finance.yahoo.com - February 26 at 9:37 AM
Clearside Biomedical Inc (CLSD) Short Interest Down 44.7% in JanuaryClearside Biomedical Inc (CLSD) Short Interest Down 44.7% in January
www.americanbankingnews.com - February 12 at 4:32 AM
Clearside Biomedicals (CLSD) Buy Rating Reaffirmed at WedbushClearside Biomedical's (CLSD) Buy Rating Reaffirmed at Wedbush
www.americanbankingnews.com - February 7 at 11:30 AM
Zacks Investment Research Downgrades Clearside Biomedical (CLSD) to SellZacks Investment Research Downgrades Clearside Biomedical (CLSD) to Sell
www.americanbankingnews.com - January 30 at 8:38 PM
Clearside Biomedical Inc (CLSD) Sees Significant Increase in Short InterestClearside Biomedical Inc (CLSD) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 28 at 1:26 AM
Clearside Biomedical Inc (CLSD) Receives Consensus Rating of "Hold" from BrokeragesClearside Biomedical Inc (CLSD) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 26 at 3:24 AM
Zacks Investment Research Lowers Clearside Biomedical (CLSD) to SellZacks Investment Research Lowers Clearside Biomedical (CLSD) to Sell
www.americanbankingnews.com - January 23 at 9:32 PM
Clearside Biomedical Inc (CLSD) Receives Consensus Recommendation of "Buy" from BrokeragesClearside Biomedical Inc (CLSD) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 1 at 6:22 AM
Clearside Biomedical, Inc. to Present at the 36th Annual J.P. Morgan Healthcare ConferenceClearside Biomedical, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 20 at 9:11 AM
Are Clearside BioMedical Inc’s (NASDAQ:CLSD) Interest Costs Too High?Are Clearside BioMedical Inc’s (NASDAQ:CLSD) Interest Costs Too High?
finance.yahoo.com - December 14 at 6:08 PM
Clearside Biomedical IncClearside Biomedical Inc
www.bloomberg.com - December 12 at 9:41 AM
Zacks Investment Research Upgrades Clearside Biomedical (CLSD) to "Hold"Zacks Investment Research Upgrades Clearside Biomedical (CLSD) to "Hold"
www.americanbankingnews.com - December 8 at 7:38 PM

SEC Filings

Clearside Biomedical (NASDAQ:CLSD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Clearside Biomedical (NASDAQ:CLSD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Clearside Biomedical (NASDAQ CLSD) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.